The inappropriate expression of the c-MET cell surface receptor in many human solid tumors necessitates the development of companion diagnostics to identify those patients who could benefit from c-MET targeted therapies. Tumor tissues are formalin fixed and paraffin embedded (FFPE) for histopathologic evaluation, making the development of an antibody against c-MET that accurately and reproducibly detects the protein in FFPE samples an urgent need. We have developed a monoclonal antibody (mAb), designated MET4, from a panel of MET-avid mAbs, based on its specific staining pattern in FFPE preparations. The accuracy of MET4 immunohistochemistry (MET4-IHC) was assessed by comparing MET4-IHC in FFPE cell pellets with immunoblotting analysis. The technical reproducibility of MET4-IHC possessed a percentage coefficient of variability of 6.25% in intra-assay and interassay testing. Comparison with other commercial c-MET antibody detection reagents demonstrated equal specificity and increased sensitivity for c-MET detection in prostate tissues. In cohorts of ovarian cancers and gliomas, MET4 reacted with ovarian cancers of all histologic subtypes (strong staining in 25%) and with 63% of gliomas. In addition, MET4 bound c-MET on the surfaces of cultured human cancer cells and tumor xenografts. In summary, the MET4 mAb accurately and reproducibly measures c-MET expression by IHC in FFPE tissues and can be used for molecular imaging in vivo. These properties encourage further development of MET4 as a multipurpose molecular diagnostics reagent to help to guide appropriate selection of patients being considered for treatment with c-MET-antagonistic drugs.
T he c-MET receptor tyrosine kinase (RTK) regulates cellular proliferation, migration, and differentiation during development and tissue homeostasis in response to its ligand, hepatocyte growth factor/scatter factor (HGF/ SF). 1,2 c-MET is one of the most frequently expressed oncogenes in human cancer (http://www.vai.org/met/) and, thus, represents an attractive therapeutic target. c-MET oncogenic activity increases through mutations, [3] [4] [5] [6] through overexpression, 7, 8 or through binding to HGF/SF. 9, 10 Activating mutations of c-MET in the germline are the cause of hereditary papillary renal carcinomas. 6 Sporadic kinase-activating mutations in c-MET are observed in sporadic renal, head and neck, hepatocellular carcinoma, non-small cell lung cancer, gastric cancer, and melanoma 8, [11] [12] [13] [14] and selective amplification of the mutated c-MET allele further enhances overall c-MET kinase activity. 15 The level of c-MET expression predicts the aggressiveness in a number of cancer types and has been associated with poor prognosis in many cancers, including those of the breast, stomach, cervix, liver, and of the head and neck (http://www. vai.org/met/).
A major advance occurred recently in the development of inhibitors of c-MET with remarkably favorable pharmacodynamic properties and low toxicity. These inhibitors prevent c-MET autophosphorylation, delay the growth of tumor xenografts, 13, [16] [17] [18] and are in clinical trials. Unfortunately, ex vivo analysis of patient cancers for c-MET expression is currently problematic. This is due to a limited number of validated monoclonal antibodies (mAbs) to c-MET that work for immunohistochemical evaluation of c-MET expression in formalinfixed and paraffin-embedded (FFPE) tissues. 19 This study reports the development and testing of an antibody, called MET4, which reacts with an epitope in the extracellular domain of c-MET in FFPE tissues. We demonstrate the specificity and reproducibility for c-MET and compare MET4 reactivity with the reactivity of commercial anti-MET antibodies. We show that MET4 reacts strongly with c-MET as expressed on cultured human cancer cells as well as by human tumor xenografts raised in immunocompromised mice and conduct an analysis with MET4 in ovarian cancers and gliomas. The data from this study strongly indicate that the MET4 antibody could prove valuable as a multipurpose companion diagnostic reagent to the growing repertoire of c-MET inhibitory drugs.
MATERIALS AND METHODS

Commercial Antibodies
The following c-Met-avid antibodies were purchased: MET C-28 (lot nos. C082 and C1207, Santa Cruz, Hercules, CA). DL-21 (category no. 05-238 MILLIPORE), 3D4 (Zymed, Invitrogen, Carlsbad, CA), MAB3729 (Chemicon, MILLIPORE). Negative and control antibodies for immunohistochemistry (IHC) were obtained from Vector Laboratories (Burlingame, CA) (mouse) or from Jackson Laboratories (Bar Harbor, ME) (rabbit).
Monoclonal Antibody Generation and Validation
Recombinant MET 25-567H and MET-928 proteins were prepared as previously described 20, 21 and recombinant fusion protein MET-IgG was purchased from R&D systems (Minneapolis, MN). Mouse mAbs were produced by injecting BALB/c mice intraperitoneally with native and sodium dodecyl sulfate-denatured MET 25-567H in complete Freund's adjuvant, followed by 2 additional injections with incomplete Freund's adjuvant. The final injection was given intraperitoneally and intravenously without adjuvant. Polyclonal antisera from immunized mice were tested by indirect immunofluorescence with formalinfixed MKN45 (MET-positive) and NIH3T3 (METnegative) cells. Spleen cells were fused with P3 Â 63AF8/ 653 myeloma cells using standard techniques 4 days after final injection. Hybridoma cells were screened for reactivity against MET by enzyme-linked immunosorbent assay (ELISA) and immunofluorescent staining. For screening, ten 96-well plates were coated with 2 mg/mL of MET25-567H in coating buffer (0.2 M Na 2 CO 3 /NaH-CO 3 , pH 9.6; 50 mL per well) overnight at 41C. The plates were then blocked with phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) (200 mL/well) overnight at 41C. Hybridoma supernatant (50 mL) was added to wells for 1.5 hours at room temperature. Plates were washed twice in washing buffer (PBS with 0.05% Tween-20), and alkaline phosphatase-coupled goat antimouse IgG (Sigma) was added (50 mL/well) at 1:2000 dilution for 1.5 hours at room temperature. After washing 4 times in washing buffer, phosphatase substrate CPnitrophenyl phosphate (Kirkegaard and Perry Laboratories) was added for 30 minutes, and absorbance was measured at 405 nm. A total of 34 hybridomas were selected based on strong reactivity with MET25-567H (A405 nm >2.0). The qualifying hybridomas were further tested against MET-928 by ELISA. Of the original panel of 34 clones, 14 hybridoma clones produced antibodies that reacted with both MET25-567H and MET-928. By testing multiple forms of the receptor, we expected to select antibodies directed against the most stable epitopes. Therefore, these 14 hybridomas were further evaluated by immunofluorescent staining against formalin-fixed human c-MET-positive MKN45 gastric carcinoma cells cocultivated with c-MET-negative NIH3T3 cells plated on a 96-well format. Hybridoma supernatant (50 mL) was added to wells for 1.5 hours at 371C. Plates were washed twice in washing buffer (PBS with 0.05% Tween-20), and Rhodamine red-conjugated goat antimouse IgG (Jackson ImmunoResearch Lab) was added (30 mL/well) at 1:100 dilution for 1.5 hours at 371C. After washing, cells were examined under a fluorescence microscope. Five positive clones were picked and expanded. Supernatants of these 5 clones were validated by IHC on formalin-fixed normal human prostate tissue sections. Clone 8G6 (designated MET4) gave the strongest signal and was subcloned twice and validated by ELISA against 3 recombinant MET proteins. Monoclonal antibody was produced using a bioreactor and MET4 was purified using protein-G affinity column by fast protein liquid chromatography.
IHC, Cell Lines and Cell Pellets
MET-overexpressing human cancer cell lines, SK-LMS-1/HGF (human leiomyosarcoma) and MNNG-HOS (human osteosarcoma) were cultured in Dulbecco's modified Eagle's medium 10% fetal calf serum. NIH 3T3, S114 (NIH 3T3 cells transfected with the human genes for HGF/SF and c-MET), 22 SW-1783, U118, U87, and U373 [human brain glioblastoma from American Type Culture Collection (ATCC)]. MCF-7 (breast cancer), OV-90, TOV-112D, IGROV1, and TOV-21G (ovarian adenocarcinoma) cells were obtained from ATCC and cultured according to their media specifications. Cell lines 1847, A2780, and OVCAR10 (ovarian adenocarcinomas) were obtained from the Pacific Ovarian Cancer Research Consortium (POCRC) (Seattle, WA). After fixation in 10% neutral buffered formalin (Anatech Ltd, Battle Creek, MI) for 30 minutes, cell layers were scraped, centrifuged for 5 minutes at 2000 rpm and all the liquid was removed. HistoGel (Richard-Allan Scientific) was melted according to manufacturer's instructions and equilibrated to 421C. Centrifuged cells were suspended in an equal volume of HistoGel and solidified on ice for 5 minutes. Formalin fixation of HistoGel-embedded cell pellet was continued overnight at 41C. Thereafter, cell pellets were placed in 70% ethanol at 41C until processing. HistoGel pellets were processed for 8 hours in a tissue processor and embedded in paraffin.
Human Tissues
Formalin-fixed and paraffin-embedded sections of ovarian cancer were obtained from the POCRC under an Institutional Review Board-approved protocol. The diagnosis of histologic subtype was obtained from the pathology report. In addition, tissue blocks entered in the tissue repository of the POCRC undergo a centralized pathology review by a board certified pathologist to confirm the presence of cancer in the tissue block. Prostate tissues were obtained under an Institutional Review Board-approved protocol from the Pacific Northwest Prostate SPORE specimen core. Tissue microarrays (TMAs) from gliomas were purchased from Cybrdi (Frederick, MD). The glioma grading was supplied in an accompanied spreadsheet and confirmed by Dr Cottingham, a neuropathologist (S.C.). Tissues on slides were stained with MET4 and other antibodies within 48 hours of sectioning or stored in a nitrogen atmosphere. Antigen retrieval was performed with Target Retrieval Solution, pH 9 (Dako, Denmark) for 20 minutes in a steaming water bath. The slides were loaded on the Dako Autostainer. All of the following incubations were performed at room temperature on the Autostainer: endogenous peroxidase activity was blocked for 8 minutes with 3% hydrogen peroxide; a protein blocking step using Dako Serum-Free Protein Block was then completed in 10 minutes. The monoclonal mouse antihuman MET4 antibody was diluted in Tris buffer/1%BSA 1:300 for staining of prostate tissues, 1:150 for staining of TMA slides and 1:500 for staining of cell pellets. The MET C-28 polyclonal antibody was diluted 1:300, 3D4 1:500, AMB3729 1:500, and DL-21 1:10 for staining of prostate tissues. For the isotype control, purified mouse IgG was diluted to match the MET4 concentration. Biotinylated antimouse or antirabbit IgG (Vector Labs) secondary antibodies were diluted at 1:200 and were applied for 30 minutes. Then, Peroxidase-conjugated Streptavidin (Jackson ImmunoResearch) was used at 1:2000 for 30 minutes. Finally, Dako Liquid 3,3 0 -diaminobenzidine (DAB)+ Substrate Chromagen System was applied for 7 minutes. The slides were counterstained with Dako Automation Hematoxylin for 2 minutes, dehydrated, and coverslipped.
For each cell pellet, a negative control was included in all IHC experiments and stained with a mouse isotype control. As a control for the MET C-28 polyclonal antibody, normal rabbit serum was used as a negative control for which no signal was detected (data not shown).
The scoring of immunohistochemically stained sections was performed as previously described. 23 Briefly, a cumulative score was derived by multiplying the percentage of positive cells by the staining intensity. Cumulative scores were divided into 4 categories (0, 1 to 100 = 1, 101 to 200 = 2, and 201 to 300 = 3) and grouped by histologic subtype (ovarian cancer) or tumor grade (glioma).
Western Blot Analysis
Subconfluent cells were lyzed in RIPA buffer with protease and phosphatase inhibitors (Roche US Pharmaceuticals, Nutley, NJ) as described. 24 Protein lysates from cell lines were measured using a Bradford assay. Samples were measured in the same assay using BSA standards ranging from 0 to 12 mg/mL. Samples were diluted such that 1 to 2 mL of sample provided measurements within the linear range of the standard curve. Samples (50 mg) were resolved on a 4% to 15% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto Immobilon-P PVDF (Millipore, Billerica, MA) or nitrocellulose transfer membranes (Bio-Rad, Hercules, CA). Membranes for the formalin-fixed Western blot were fixed in 2% neutral buffered formalin Z-fix (Anatech Ltd, Battle Creek, MI) for 20 minutes and washed in PBS. Antigen retrieval was performed with Target Retrieval Solution, pH 9 (Dako, Carpinteria, CA) for 20 minutes in a steamer (Black and Decker). The membrane was blocked with 5% milk at room temperature. Antibodies for probing of membranes were: MET C-28 at 1:250, 1.5 hours; MET4 at 1:1000, and 3D4 at 1:500 over night. Donkey antirabbit IgG-horseradish peroxidase (Amersham) was used at 1:5000 or AlexaFluor 680 goat antimouse IgG (Molecular Probes) was used at 1:10,000. Protein bands were detected by a chemiluminescence reagent (Pierce) or Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, Nebraska). Images scanned on the Odyssey Infrared Imaging System were scanned using the 700 nm channel at an intensity of 5.0. The signal intensity of the c-MET-specific bands was measured using 1-dimensional gel analysis module in the ImageQuant TL software. Background was subtracted using the ''rolling ball'' tool.
Digital Image Analysis of IHC-stained Cell Pellet Sections
Slides with sections of cell pellets stained with MET4 were spectrally imaged using a CRI Nuance camera system (www.cri-inc.com). Six to 10 images were collected from each slide. Emission was measured between 420 and 720 nm in 20 nm increments. The resulting image cubes were converted to optical density units, and were mathematically unmixed into their individual DAB and hematoxylin components using spectrums deduced from control specimens and saved in a spectral library. The DAB stain was pseudo-colored red to increase contrast. The hematoxylin was pseudo-colored blue and the images were converted to pseudo-fluorescent format for quantification.
The spectrally unmixed images were then quantified with software developed by our laboratory that identified the mean DAB optical density and the number of pixels 25 The cell count was determined by counting the nuclei (as identified by hematoxylin counter stain) using the connected component algorithm 26 on pixels whose hematoxylin optical density was above background. A count of total nuclei was determined after using an auto high pass threshold filter. The threshold for positive MET4 staining was set using an intensity threshold filter value of 171 intensity units. This threshold parameter was defined using c-MET-negative control cell lines (A2780, OV-CAR10, and TOV-112D) and restricting the number of positive pixels to 0.1%. This is similar to the percentage of positive area statistics. 27 These counts were then used to determine the percent positive MET4 cells for each sample pellet.
Statistical Analysis
For statistical analysis, the Pearson's correlation coefficient was calculated using Microsoft Excel software. Components of variance for biologic variability within the TOV21G cell pellet and for technical variability were estimated from a mixed-model analysis by employing the MIXED procedure in SAS (www.sas.com). The technical variability (attributable to antibody staining and image acquisition) was divided by the mean to obtain the percentage coefficient of variability (%CV).
Fluorescence-activated Cell Sorting Analysis
SK-LMS-1/HGF and MNNG-HOS were labeled with MET4 followed by fluorescein-conjugated antimouse IgG1. Fluorescence-activated cell sorting (FACS) analysis was carried out using a FACS Calibur flow cytometer and the CellQuest analysis program (Becton Dickinson).
Tumor Xenografts and Nuclear Imaging With MET4
SK-LMS-1/HGF and MNNG-HOS cells were used for xenograft induction. Female athymic nude (nu/nu) mice at about 2 months of age received subcutaneous injections of cell suspension (5 Â 10 5 cells) in the posterior aspect of the right thigh. Tumors developed for 3 to 4 weeks, reaching 0.5 cm or more in greatest dimension by external caliper measurement before imaging. Mice were housed in small groups and given ad libitum access to mouse chow and drinking water under conditions approved by the institutional animal care committee. For nuclear imaging experiments, MET4 was equilibrated in 0.25 M sodium phosphate buffer, pH 7, stored frozen in small aliquots, and thawed just before labeling. Protein radioiodination was performed as previously described. 28 125 I was purchased as NaI [480 to 630 MBq (13 to 17 mCi) per mg iodine] from Amersham Corp (Arlington Heights, IL). Biodistribution studies were performed as previously described. 29 Host mice were imaged and scintigrams were analyzed by established methods. 28 In brief, each tumor xenograft-bearing mouse received 125 I-MET4 (B160 mCi, r0.1 mL; injected within 24 h of radiolabeling) intravenously by tail vein injection under light inhalation anesthesia. Just before each imaging session, each mouse was given up to 13 mg/kg xylazine and 87 mg/kg ketamine subcutaneously in the interscapular region. Serial posterior whole-body g camera images of each mouse were acquired beginning as early as 1 hour after 125 I-MET4 injection and continuing for several days postinjection. Sedated mice were placed in groups on top of an inverted camera head with a protective layer over the collimator and taped to the layer to maintain optimum limb extension. Images of 125 I activity were acquired on a remanufactured ZLC-Scintron camera (MiE America) with a low-energy, high-sensitivity collimator. Acquisitions were obtained over a period of 15 to 30 minutes.
Relative activity was determined by computerassisted region-of-interest analysis for each tumor, for total body, and for appropriate background regions at each imaging time point. These data are expressed as background-corrected and decay-corrected activity ratios. Graphical and statistical analyses of the converted data used the program Excel (Microsoft).
RESULTS
Development of an Anti-MET Monoclonal Antibody for Detection of c-Met in Formalin-fixed Tissues
The limitations of available antibodies to measure c-MET expression in formalin-fixed tissues led to our development of the monoclonal MET4 antibody. Polyclonal antisera are commonly affected by lot-to-lot variability from differences in the animals in which they are raised. When we tested several lots of the polyclonal rabbit antisera to c-MET that is most commonly used for c-MET analysis (MET C-28), we observed lot-to-lot differences in prostate tissue as previously shown 19 (Fig. 1 ). Although lot A showed the expected staining of basal prostate epithelial cells, lot B revealed punctate cytoplasmic staining in secretory cells. To overcome the problems with polyclonal antibodies, we generated mAbs that are easier to standardize for a clinical application. The immunogen was designed to obtain c-MET antibodies that bind to the extracellular domain (ectodomain). To identify mAbs directed against the most prevalent and least variable epitopes, our selection process included multiple forms of the ectodomain of c-MET, including MET 25-567H, MET-928, MET-IgG, and c-MET on the surface of formalin-fixed MKN45 cells ( Table 1) . As a final screen, we used sections of archival normal prostate tissues (Table 1 ). Hybridoma supernatant ''MET4'' gave the strongest specific staining, consistent with the distinct subcellular pattern of c-MET receptor expression in prostate [30] [31] [32] (Fig. 1 ). MET4 was further validated by staining cocultures of c-MET-reactive MKN45 cells and nonreactive NIH3T3 cells that were fixed in 10% formalin. The immunofluorescent staining was specifically observed along the membrane of MKN45 cells and coincided with immunoreactivity of MET C-28 ( Fig. 2A ).
Avidity of MET4 for MET in Formalin-fixed Cells
To confirm the reactivity of MET4 with c-MET, we probed a Western blot with MET4. To approximate the conditions of formalin-fixation in tissues, Western blot membranes were treated with 10% formalin and subjected to the same type of antigen retrieval as we applied to tissue sections. MET4 did not react with c-MET in IGROV1 ovarian cancer cells in Western blots, which express large amounts of the antigen. However, exposing the membrane to formalin and steam to mimic IHC conditions of antigen retrieval facilitated MET4 binding to c-MET ( Supplementary Fig. 6 ). MET4 did not react in a specific fashion with the A2780 cell line, which does not express c-MET RNA ( Supplementary Fig. 7) . The immunofluorescence and Western blotting results demonstrate that MET4 binds to a specific epitope on c-MET that is sensitive to denaturation and recovered by formalin-fixation and/or antigen retrieval.
To further validate the specificity of MET4 in formalin-fixed cell preparations, we analyzed 2 panels of cell lines (Fig. 2B ). Cell lines were selected based on c-MET expression levels. The first panel consisted of 7 ovarian cancer cell lines. These cell lines express variable amounts of c-MET or none at all: A2780, OVCAR10, and TOV-112D do not express c-MET RNA or protein.
The absence of Met RNA was confirmed by polymerase chain reaction ( Supplementary Fig. 6 ). OV-90 and TOV21G express some c-MET, whereas IGROV1 cells express high levels. We also examined a series of cell pellets comprised predominantly of glioblastoma tumor cell lines (U118, DBTRG, SW1783, U87, and U373), NIH3T3 cells transfected with human HGF and c-MET (S114) 22 and the 2 negative cell lines (NIH3T3 and MCF7). To evaluate the specificity of MET4 in formalinfixed preparations, we processed formalin-fixed HistoGelembedded cell pellets in a tissue processor and embedded them in paraffin. Cell pellets on slides were stained with MET4 and the immunohistochemical reactivity was compared with MET C-28 reactivity in a Western blot. MET4 reacted with only the formalin-fixed cell pellets that were positive for c-MET by Western blot analysis (Figs. 2B, C), but not with those negative for c-MET. Further, MET4 does not crossreact with mouse c-MET.
Reproducibility of MET4 Immunohistochemical Measurements
As the results demonstrate that the novel MET4 antibody specifically binds c-MET in FFPE cell preparations, we tested its reproducibility in TOV21D cells, which express c-MET at intermediate levels. The assay reproducibility is a critical factor in the development of an antibody for immunohistochemical tests. We analyzed the consistency of MET4 staining intensities in FFPE cell pellets among replicate stains on the same day (intra-assay reliability) and slides stained on 3 different days (interassay reliability) ( Table 2 ). In addition, we compared the staining results from 2 separate lots of MET4 antibody. The 2 lots of purified antibody, showed good correlation. However, we noticed that in general, images taken at different areas of the cell pellet possess significant variability in staining intensity, which reduced the correlation coefficient in the lot-to-lot comparison (correlation coefficient of s = 0.75). To obtain an accurate assessment of intra-assay and interassay reproducibility, we therefore calculated the intraclass correlation coefficient. This statistical method separates biologic and technical variabilities and revealed that the biologic variability amounted to 98% of the total variability and the technical variability only to 2%. Consequently, the %CV for technical variability was 6.8% for the intraassay and 6.2% for the interassay variability. These data demonstrate that MET4-IHC possesses excellent reliability and lot-to-lot consistency for analysis of formalinfixed cell preparations.
Comparison of MET4 to Other c-MET Reactive Antibodies
Several mAbs against c-MET have been developed and shown to bind c-MET in formalin-fixed tissues ( Table 3 ) and in Western blots (and data not shown). 19 Although MET4 and DL21 bind to extracellular epitopes on the c-MET receptor, 3D4 and MAB3729 react with the intracellular portion of c-MET. After titrating each antibody to optimize its signal-to-noise ratio, we observed significant differences in cell type-specific immunoreactivity between MET4 and the other antibodies. Compared with MET4, the staining with DL21 was weak in prostate tissue, even at a high antibody concentration. The strongest immunoreactivity was observed in granular inflammatory cells, which are dispersed in the stroma. Endothelial cells reacted weaker with DL21 than with MET4. The MAB3729 antibody strongly stained basal, but not luminal prostate epithelial cells. In some glands, this antibody also reacted with the cytoplasm and nucleus of luminal cells, a staining pattern not observed with the other antibodies. The MAB3729 antibody intensely stained the prostate stroma. The 3D4 antibody reactivity in the prostate epithelium is most similar to MET4. However, the stroma is more reactive, and endothelial cells are rarely positive.
Although all antibodies react with c-MET in basal cells, MET4 best demonstrated c-MET expression in luminal epithelial cells at the basal-lateral plasma membrane. In addition to prostate epithelial cells, endothelial cells and subpopulations of inflammatory cells express c-MET. The cytoplasm of stromal cells is weakly and diffusely positive for c-MET staining, which is consistent with the detection of c-MET primary prostate stromal cells by immunoblotting (data not shown).
Immunohistochemical analysis reveals high specificity of MET4 and resistance to suboptimal tissue fixation (data not shown). We conclude that as a result of the selection process, MET4 recognizes an epitope that is frequently and faithfully presented.
c-MET Expression in Ovarian Cancers and Gliomas
To evaluate the specificity of MET4-IHC in archival FFPE tissues, we analyzed sections of ovarian cancer tissues and a TMA of gliomas. MET4 possessed high staining specificity for ovarian cancer cells, endothelial 
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Granular cells in the prostate stroma 4+ 0 2 + *The antibody dilution was optimized to obtain the best signal-to-background ratio. The signal was evaluated by the staining intensity of basal prostate epithelial cells and the background staining was judged by the staining of the extracellular matrix of the stroma and the cytoplasm of secretory cells. cells, a subpopulation of cells in the ovarian stroma, and of plasma cells. Nuclear staining was not observed (Fig. 3A) . Histologic subtypes of ovarian cancers included serous, endometrioid, and clear cell, but not mucinous cancers, with all cancers in International Federation of Gynecology and Obstetrics stage III-IV. All 29 ovarian cancers showed MET4-IHC reactivity ( Table 4 ). No significant statistical differences were observed in MET4 staining intensity across subtypes of ovarian cancer. Clear cell cancers, which are considered the most aggressive subtype, did not demonstrate greater reactivity than other histologic subtypes. Endothelial cells are MET4 positive and were used as an internal reference to confirm adequate tissue quality and antigen retrieval for MET4 and to normalize staining intensities between slides.
To evaluate the specificity of MET4-IHC and expression of c-MET in brain tumors, we stained a tissue array of gliomas. The tissue microarray contained 18 gliomas in triplicate cores. In addition, there were 3 samples of normal brain tissues ( Table 5 , Fig. 3B ). Neurons and reactive astrocytes stained strongly with MET4, whereas oligodendrocytes did not. Surprisingly, endothelial cells varied in c-MET expression, including endothelial cells of tumor vasculature. Five of 18 gliomas were c-MET negative, whereas 3 high-grade gliomas stained very strongly with MET4. Altogether, 63% of gliomas expressed c-MET, and the expression level increased with tumor grade.
MET4 Binding by FACS Analysis
To evaluate the suitability of MET4 for binding studies, we performed FACS analysis on established c-MET-overexpressing human cancer cell lines grown in culture ( Fig. 4) and radionuclear imaging studies of 125 I-MET4 uptake and retention by c-MET-overexpressing human tumor xenografts raised in immunocompromised mice (Fig. 5 ).
Just as we have observed by FACS analysis with other c-MET-avid immunologic probes, 33 incubation of MET-overexpressing cell lines with MET4 and a fluorescent second antibody resulted in significant upward shifts of fluorescence intensity (Fig. 4) , indicating high avidity of MET4 for an epitope exposed at the cell surface.
Nuclear images of c-Met-overexpressing human tumor xenografts in host nude mice injected with 125 I-MET4 are qualitatively and quantitatively comparable with the best tumor images we have obtained with any other c-MET-avid or HGF/SF-avid antibodies (Fig. 5A ). 28, 29 Moreover, by biodistribution analysis (Fig. 5B ), MET4 is exceptionally durable for in vivo 
DISCUSSION
Here we describe the generation and characterization of a multipurpose c-MET mAb and show examples of its potential usefulness in measuring c-MET in human cancers. The c-MET RTK is particularly difficult to measure in FFPE tissues because of limited reagent availability and/or insufficient sensitivity and lack of validation of commercially obtainable antibodies. Moreover, the stability of c-MET epitopes seems to require proper formalin-fixation or storage of FFPE tissue blocks (BSK unpublished observation). We spent several years developing and rigorously testing FFPE-suitable c-MET antibodies before obtaining MET4. The MET4 hybridoma was chosen based on a stringent screening assay in FFPE prostate tissues and a rigorous final selection of established specific reactivity in FFPE prostate epithelial and endothelial cells (Fig. 1, Table 1 ). We believe that this screening approach greatly enhanced obtaining an antibody that recognizes an epitope in extracellular domain of c-MET epitope in FFPE tissues. Thus, the MET4 epitope is either more hardy, available, or MET4 possesses high affinity than other antibodies. MET4 also reacted stronger with c-MET in cell-cell junctions at the basolateral cell membrane, compared with other c-MET antibodies ( Table 3) . MET4 staining in different cell types seems to be faithful when compared with independent measurements of c-Met abundance by immunoblotting. Further, MET4 staining was reproducible in replicate stains on the same day (%CV = 6.8), on different days (%CV = 6.2), and when comparing 2 separate lots of MET4 ( Table 2 ). The special characteristics of MET4 0  2 1  3 4  5  3 7  1  2 2  3 5  7  3 6  2  1 3  2 1  3  1 6  3  6  10  3  11  Total  62  100  18  100 A tissue microarray of 18 gliomas on triplicate cores was stained with the MET4 antibody. MET4 reactivity was assessed by multiplying the relative staining intensity and the percentage of positive cells. The overall score is expressed on a categorical scale from 0 to 3. warrants further development of this mAb as a diagnostic reagent for ex vivo measurement of c-MET in clinical samples.
Gonzatti-Haces et al 34 first employed a rabbit polyclonal anti-MET C-28 antibody to analyze c-MET in FFPE tissues and most subsequent studies used various lots of anti-MET C-28 polyclonal antibody (Santa Cruz, Hercules, CA). A systematic comparison of commercial MET antibodies, including 3 mAbs and 2 separate lots of MET C-28 with the AQUA technology clearly demonstrated a greater than expected amount of variability in a breast cancer tissue microarray study. 19 This report illustrates the difficulty of generating reliable c-MET detection reagents.
Although c-MET activation through somatic gene mutation or overexpression has been clearly observed in certain cancer types, these mechanisms seem to be infrequent in primary ovarian cancers or gliomas. Previous analyses of c-MET expression in gliomas demonstrated increased c-MET expression in grade IV glioblastoma similar to the observation in this study and overall frequencies of high c-MET expression or c-MET gene amplifications in 10% to 30%. 35, 36 Overexpression of c-MET through duplication of the c-MET gene in double minute chromosomes was noted in 3/18 grade IV and 1/18 grade II gliomas. 37 In contrast to gliomas, all ovarian cancers expressed c-MET, and 7/28 had high levels of c-MET expression. A previous study observed lower c-MET expression in endometrioid ovarian cancer and a lower fraction of ''intense'' c-MET staining across the other histologic subtypes. 38 Potentially, the heightened reactivity of MET4 in ovarian cancers is due to increased sensitivity and binding affinity compared with other c-MET antibodies. We propose that the true relevance of c-MET overexpression in ovarian cancer, gliomas, and other cancer types-as well as its relationship to the therapeutic efficacy of c-MET inhibitory drugs-would best be evaluated in one or more clinical studies that correlate treatment responses with c-MET expression levels.
